Superficial vein thrombosis (SuVT) is a thrombo-inflammatory process in a superficial vein, with an estimated annual incidence of 64–131 per 100,000 person-years. Once considered benign, it now carries a recognized ~10% risk of progression to DVT or PE and approximately 25% of patients have concomitant DVT at diagnosis. [1-2] The following is a comprehensive clinical summary organized for emergency medicine and primary care workflows.
1. History
- Location and onset: Ask about the specific limb, vein distribution, and acuity of symptoms (sudden vs. gradual)
- Symptom characterization: Localized pain, tenderness, warmth, redness along a superficial vein; pruritus; palpable cord [1]
- Timing and triggers: Recent IV catheter placement, recent surgery, trauma, prolonged immobility, long travel, pregnancy/postpartum period [3]
- Progression: Proximal extension of redness/cord, worsening swelling, new diffuse limb edema
- Associated symptoms: Dyspnea, chest pain, pleurisy (concerning for PE); calf pain/swelling (DVT extension) [1]
- Important negatives: Absence of fever/systemic toxicity (helps distinguish from septic thrombophlebitis or cellulitis), no IV drug use, no recent catheter
2. Alarm Features
- SuVT within 3 cm of the saphenofemoral or saphenopopliteal junction — treat as equivalent to DVT [1][4]
- Thrombus >5 cm in length or extending above the knee — requires anticoagulation [1][5]
- New-onset dyspnea or chest pain — evaluate for PE with CTPA [1]
- Rapidly extending erythema, high fever, purulent drainage — consider septic thrombophlebitis (especially with IV catheter history)
- Bilateral or migratory thrombophlebitis (Trousseau sign) — high suspicion for occult malignancy [6]
- Diffuse extremity edema — suggests concomitant DVT
3. Medications
- Relevant contributors: Oral contraceptives, hormone replacement therapy (estrogen/progesterone), tamoxifen, chemotherapy agents [2-3]
- Common treatments:
- NSAIDs (oral ibuprofen, naproxen) for pain/inflammation in mild cases [1]
- Fondaparinux 2.5 mg SC daily × 45 days — first-line anticoagulant for SuVT ≥5 cm (CALISTO trial: absolute risk reduction 5% for VTE vs. placebo) [5][7]
- Rivaroxaban 10 mg PO daily × 45 days — noninferior alternative (SURPRISE trial) [1]
- Enoxaparin 40 mg SC daily — alternative LMWH option [1]
- Therapeutic-dose anticoagulation (e.g., full-dose DOAC) if SuVT is within 3 cm of deep vein junction [1][4]
- Topical options: Heparin ointment/gel for symptom relief (limited RCT data; requires compounding pharmacy in the US) [1]
- Cautions: Avoid anticoagulation without assessing bleeding risk; NSAIDs alone have not been shown to prevent VTE progression [4]
4. Diet
- No specific dietary triggers or restrictions for SuVT
- Hydration: Adequate hydration to reduce venous stasis, particularly in immobilized or postoperative patients
- If on warfarin (less commonly used), standard vitamin K dietary counseling applies
5. Review of Systems
- Pulmonary: Dyspnea, chest pain, hemoptysis (PE screening)
- Lower extremity: Unilateral leg swelling, calf tenderness (DVT)
- Constitutional: Fever, chills, night sweats, unintentional weight loss (infection, malignancy)
- Skin: Varicose veins, skin ulceration, hyperpigmentation (chronic venous insufficiency)
- Hematologic: History of easy bruising, prior clots, family history of clotting disorders
- Rheumatologic: Oral/genital ulcers, joint pain (Behçet disease can present with thrombophlebitis) [6]
6. Collateral History and Family History
- Family history of VTE, thrombophilia (Factor V Leiden, prothrombin 20210A mutation, protein C/S deficiency) [2]
- Social context: IV drug use (upper extremity SuVT), recent hospitalization, immobility
- Obstetric history: Pregnancy losses, prior pregnancy-related VTE
- Cancer screening status: Up to 16% of SuVT patients have cancer; unprovoked SuVT in the absence of varicose veins warrants age-appropriate cancer screening [1][3]
7. Risk Factors
- Varicose veins — most common association [1]
- Pregnancy and postpartum (up to 12 weeks) [3]
- Active cancer — associated with higher 3-month VTE (4.5% vs. 1.9%), major bleeding, and death [1]
- Recent surgery, trauma, or immobilization [2]
- IV catheter placement — primary cause of upper extremity SuVT [1]
- Oral contraceptives / HRT [3]
- Obesity, age >60 years [3]
- Inherited thrombophilia (weakly associated; Factor V Leiden OR ~1.5) [2][8]
- Autoimmune/inflammatory conditions (lupus, Behçet disease) [3][6]
- Male sex — independent risk factor for VTE progression (HR 2.63) [1]
- History of prior VTE or SuVT (HR 2.18 for thrombotic events) [1]
8. Differential Diagnosis
- Cellulitis — diffuse erythema without palpable cord; may have systemic signs
- DVT — deeper pain, diffuse limb edema; no superficial cord; requires ultrasound
- Lymphangitis — red streaking along lymphatic channels, often with proximal lymphadenopathy
- Erythema nodosum — tender nodules on shins, bilateral, no cord
- Insect bite / localized soft tissue infection — focal, no linear distribution
- Hematoma — ecchymosis, history of trauma
- Phlebitis without thrombosis — inflammation only; ultrasound shows no thrombus
- Vasculitis — palpable purpura, systemic symptoms [1]
- Mondor disease — SuVT of the chest wall, breast, or penis (same pathology, different location) [1]
9. Past Medical History
- Prior episodes of SuVT or DVT/PE
- Known varicose veins or chronic venous insufficiency
- Active or prior malignancy
- Known thrombophilia
- Autoimmune disease (lupus, Behçet, antiphospholipid syndrome)
- Recent surgery or hospitalization
- Pregnancy history
10. Physical Exam
- Hallmark finding: Tender, erythematous, palpable cord along a superficial vein [1]
- Localized warmth, induration of surrounding tissue
- In a retrospective study: 76.9% had localized pain, 60.1% had a palpable cord, 58.2% had erythema [1]
- Assess for DVT: Measure calf/thigh circumference bilaterally; check for pitting edema, Homan sign (low sensitivity)
- Vital signs: Fever suggests septic thrombophlebitis; tachycardia/hypoxia raises concern for PE
- Varicose veins: Document presence and distribution
- Upper extremity: Inspect IV catheter sites; assess for cord along cannulated vein
- Measure cord length if possible — >5 cm is a treatment threshold [1]
11. Lab Studies
- Routine labs are not required for straightforward cases
- If anticoagulation is planned: CBC with platelets, PT/aPTT, renal and hepatic function (per NCCN) [9]
- D-dimer: Sensitivity only 48–74.3% for SuVT — not reliable for ruling out SuVT. However, may be useful if DVT/PE is suspected [1]
- Consider hypercoagulability workup in unprovoked SuVT without varicose veins, recurrent SuVT, or young patients: antiphospholipid antibodies, Factor V Leiden, prothrombin gene mutation
- Age-appropriate cancer screening if unprovoked and no varicose veins [1]
12. Imaging
- First-line: Duplex ultrasonography — reference standard for confirming diagnosis, assessing thrombus extent, and ruling out concomitant DVT [1][10]
- Indications for ultrasound: [1][5]
- Diagnostic uncertainty
- SuVT above the knee (high prevalence of concomitant proximal DVT)
- Suspected thrombus near the saphenofemoral or saphenopopliteal junction
- Risk factors for DVT (cancer, prior VTE, male sex)
- Worsening or persistent symptoms
- Ultrasound may not be necessary in patients with classic findings, small area of induration, and no major risk factors [1]
- CTPA: If new dyspnea or chest pain develops — evaluate for PE [1]
- Repeat ultrasound in 7–10 days: For SuVT <5 cm or below the knee managed conservatively, to assess for progression [9]
13. Special Tests
- No validated clinical scoring system exists specifically for SuVT (unlike Wells score for DVT/PE)
- Point-of-care ultrasound (POCUS): Can be used in the ED to identify a non-compressible superficial vein and assess for DVT [10]
- Compression ultrasonography (CUS): Same principle as DVT diagnosis — lack of compressibility and impaired flow [10]
- Thrombophilia testing: Consider in unprovoked, recurrent, or atypical cases (not routinely recommended acutely)
14. ECG
- Not routinely indicated for isolated SuVT
- Obtain ECG if: Chest pain, dyspnea, tachycardia, or hypoxia (evaluate for PE)
- Concerning patterns: Sinus tachycardia, right heart strain (S1Q3T3, right axis deviation, RBBB) — suggestive of significant PE
15. Assessment
Superficial vein thrombosis is no longer considered a benign, self-limiting condition. Key clinical decision points:
- ~10% progress to DVT/PE; ~25% have concomitant DVT at diagnosis [1-2]
- Highest VTE risk occurs in the first 3 months after diagnosis (3.4% incidence; HR 71.4 vs. general population) [11]
- Worse prognosis associated with: cancer, history of VTE, absence of varicose veins, male sex, saphenofemoral junction involvement [1]
- Atypical presentations: migratory thrombophlebitis (malignancy), bilateral (autoimmune), Mondor disease (chest/breast/penile) [1][6]
16. Treatment Plan
Treatment is stratified by thrombus size, location, and risk factors: [1][4-5][9]
Conservative therapy (small, low-risk SuVT <5 cm, below knee, away from deep veins):
- Warm compresses, limb elevation
- Oral NSAIDs for pain/inflammation
- Elastic compression stockings (20–30 mmHg)
- Remove causative IV catheter if applicable [9]
Prophylactic-dose anticoagulation (SuVT ≥5 cm or persistent/worsening symptoms):
- Fondaparinux 2.5 mg SC daily × 45 days — best-studied, first-line [5][7]
- Rivaroxaban 10 mg PO daily × 45 days — noninferior oral alternative [1]
- Enoxaparin 40 mg SC daily — alternative [1]
Therapeutic-dose anticoagulation (SuVT within 3 cm of saphenofemoral/saphenopopliteal junction):
- minimum 3 monthsJAMA + 2[1][4][9]
The following NCCN algorithm summarizes the diagnostic and treatment pathway:
The following table from the 2025 JAMA review summarizes the evidence for each treatment modality:
Key guideline note: The Society for Vascular Surgery (2023) recommends against using prophylactic or therapeutic LMWH and NSAIDs alone for saphenous trunk SuVT, as both have failed to prevent VTE, and favors fondaparinux or rivaroxaban. [4]
17. Disposition
- Discharge (majority of cases): Most SuVT is managed as an outpatient with conservative therapy ± anticoagulation [1][12]
- Observation/admission considerations:
- Concomitant DVT or PE identified
- Septic thrombophlebitis requiring IV antibiotics
- Hemodynamic instability or significant PE symptoms
- Inability to arrange timely outpatient follow-up for high-risk patients
- Specialist consultation triggers:
- Vascular surgery: SuVT at the saphenofemoral junction, recurrent SuVT, consideration for venous ablation
- Hematology: Unprovoked SuVT, suspected thrombophilia, recurrent VTE
- Oncology: If occult malignancy is suspected
18. Follow Up / Return Precautions
- Follow-up timing: Primary care or vascular medicine within 1–2 weeks; sooner if symptoms worsen [1]
- Repeat ultrasound: Within 7–10 days for conservatively managed SuVT <5 cm to assess for progression; within 1 week if symptoms worsen [1][9]
- Return immediately for:
- New or worsening leg swelling (DVT extension)
- Shortness of breath, chest pain, hemoptysis (PE)
- Fever, spreading redness, purulent drainage (septic thrombophlebitis)
- Proximal extension of the palpable cord
- Patient counseling:
- If treated with topical agents only, seek care if no improvement within 7 days [1]
- Encourage ambulation (not bed rest)
- Compression stockings for symptom relief
- Complete full anticoagulation course if prescribed (typically 45 days)
- Expected recovery: Symptoms typically improve within 1–2 weeks with appropriate therapy; residual induration may persist for weeks to months
References
1. Superficial Vein Thrombosis. — Piazza G, Krishnathasan D, Hamade N, et al. The Journal of the American Medical Association. 2025.
2. Superficial Vein Thrombosis. — Piazza G, Krishnathasan D, Hamade N, et al. The Journal of the American Medical Association. 2025.
3. Superficial Vein Thrombosis. — Piazza G, Krishnathasan D, Hamade N, et al. The Journal of the American Medical Association. 2025.
4. Treatment for Superficial Thrombophlebitis of the Leg. — Di Nisio M, Wichers IM, Middeldorp S. The Cochrane Database of Systematic Reviews. 2018.
5. Treatment for Superficial Thrombophlebitis of the Leg. — Di Nisio M, Wichers IM, Middeldorp S. The Cochrane Database of Systematic Reviews. 2018.
6. What Is Superficial Vein Thrombosis?. — Angulo MI, Mauro AC, Vela M. The Journal of the American Medical Association. 2025.
7. What Is Superficial Vein Thrombosis?. — Angulo MI, Mauro AC, Vela M. The Journal of the American Medical Association. 2025.
8. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society Clinical Practice Guidelines for the Management of Varicose Veins of the Lower Extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine. — Gloviczki P, Lawrence PF, Wasan SM, et al. Journal of Vascular Surgery. Venous and Lymphatic Disorders. 2024.
9. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society Clinical Practice Guidelines for the Management of Varicose Veins of the Lower Extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine. — Gloviczki P, Lawrence PF, Wasan SM, et al. Journal of Vascular Surgery. Venous and Lymphatic Disorders. 2024.
10. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. — Stevens SM, Woller SC, Kreuziger LB, et al. Chest. 2021.
11. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. — Stevens SM, Woller SC, Kreuziger LB, et al. Chest. 2021.
12. Superficial (Nodular) Thrombophlebitis as a Heterogeneous Entity With Distinctive Clinico-Pathological Aspects: Correlation With the Underlying Conditions. — Gales L, Cribier B, Lipsker D, Lenormand C. Journal of the European Academy of Dermatology and Venereology : JEADV. 2023.
13. Superficial (Nodular) Thrombophlebitis as a Heterogeneous Entity With Distinctive Clinico-Pathological Aspects: Correlation With the Underlying Conditions. — Gales L, Cribier B, Lipsker D, Lenormand C. Journal of the European Academy of Dermatology and Venereology : JEADV. 2023.
14. Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review. — Chopard R, Albertsen IE, Piazza G. The Journal of the American Medical Association. 2020.
15. Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review. — Chopard R, Albertsen IE, Piazza G. The Journal of the American Medical Association. 2020.
16. Increased Risk of Venous Thrombosis in Persons With Clinically Diagnosed Superficial Vein Thrombosis: Results From the MEGA Study. — van Langevelde K, Lijfering WM, Rosendaal FR, Cannegieter SC. Blood. 2011.
17. Increased Risk of Venous Thrombosis in Persons With Clinically Diagnosed Superficial Vein Thrombosis: Results From the MEGA Study. — van Langevelde K, Lijfering WM, Rosendaal FR, Cannegieter SC. Blood. 2011.
18. Cancer-Associated Venous Thromboembolic Disease. — Updated 2026-05-05. National Comprehensive Cancer Network.
19. Cancer-Associated Venous Thromboembolic Disease. — Updated 2026-05-05. National Comprehensive Cancer Network.
20. A current approach to superficial vein thrombosis. — Ellis MH, Fajer S. European Journal of Haematology. 2013.
21. A current approach to superficial vein thrombosis. — Ellis MH, Fajer S. European Journal of Haematology. 2013.
22. Risk of Venous and Arterial Thrombotic Events in Patients Diagnosed With Superficial Vein Thrombosis: A Nationwide Cohort Study. — Cannegieter SC, Horváth-Puhó E, Schmidt M, et al. Blood. 2015.
23. Risk of Venous and Arterial Thrombotic Events in Patients Diagnosed With Superficial Vein Thrombosis: A Nationwide Cohort Study. — Cannegieter SC, Horváth-Puhó E, Schmidt M, et al. Blood. 2015.
24. Controversies in Venous Thromboembolism: To Treat or Not to Treat Superficial Vein Thrombosis. — Beyer-Westendorf J. Hematology. American Society of Hematology. Education Program. 2017.
25. Controversies in Venous Thromboembolism: To Treat or Not to Treat Superficial Vein Thrombosis. — Beyer-Westendorf J. Hematology. American Society of Hematology. Education Program. 2017.